![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
August 25, 2023
The changes broaden eligibility for prostate cancer patients and make baseline scanning easier for sites in this phase 3 trial using PET imaging to guide treatment for recurrence
August 25, 2023
The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy.
June 30, 2023
This phase 2 trial is testing how well FDG-PET/CT imaging can predict response to standard-of-care neoadjuvant therapy in patients with HER2-positive breast cancer
June 30, 2023
This phase 2 trial is evaluating the activity of nilotinib-paclitaxel in patients with solid tumors and exploring predictive biomarkers of response and resistance
June 30, 2023
This phase 3 study aims to determine the optimal sequencing of surgery, chemotherapy, and chemoradiotherapy for patients with cancer of the penis
June 30, 2023
Researchers presented numerous research abstracts and trial updates at the 2023 ASCO Annual Meeting
April 19, 2023
ComboMATCH researchers are discovering new drug combinations that show promise for patients with advanced cancers, based on strong pre-clinical in vivo evidence of therapeutic effectiveness
April 19, 2023
This phase 2 study is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
February 10, 2023
This phase 3 study is comparing the efficacy of intravesical chemotherapy after surgery to the usual approach of intravesical immunotherapy after surgery
February 10, 2023
Even as screening mammography volumes remain below pre-pandemic levels, TMIST continues to enroll women at a strong pace
February 10, 2023
These three trials are open and enrolling adults with multiple myeloma or at high risk of developing the disease
December 20, 2022
This study is investigating the safety and efficacy of venetoclax, a BCL-2 inhibitor, in combination with vincristine sulfate in the relapsed or refractory ALL population